Posted: December 22, 2012 at 4:42 pm
Hair StemCell Transplantation - Donor-Regrowth - Day-7 - Part-1
This video shows the donor area 7 days after Hair Stem Cells Transplantation (HST) extractions. The motion of the video-microscope starts from the RIGHT ear, up and down towards the occiput. SEE ALSO PART 2 !!From:146909Views:14 0ratingsTime:09:33More inScience Technology
Read the original:
Hair StemCell Transplantation - Donor-Regrowth - Day-7 - Part-1 - Video
Posted: December 22, 2012 at 4:42 pm
Hair StemCell Transplantation - Donor-Regrowth - Day-7 - Part-2
This video shows the donor area 7 days after Hair Stem Cells Transplantation (HST) extractions. The motion of the video-microscope starts from LEFT ear, up and down towards the occiput. SEE ALSO PART 1 !!From:146909Views:0 0ratingsTime:12:59More inScience Technology
Read the original post:
Hair StemCell Transplantation - Donor-Regrowth - Day-7 - Part-2 - Video
Posted: December 22, 2012 at 4:42 pm
SCMU -promotion video
stem cells #39; scientific club - Mansoura UniversityFrom:ali mowafyViews:0 0ratingsTime:02:19More inFilm Animation
Here is the original post:
SCMU -promotion video - Video
Posted: December 22, 2012 at 4:42 pm
Stem Cell Therapy Market in Asia-Pacific to 2018 Market Research Report
Report provides (www.marketresearchreports.com an in-depth analysis on stem cell research and development in India, China, Japan, South-Korea and Singapore. The report market analysis and forecasts for CABG, LSCT, Type 1 DM, Type 2 DM, Hearticellgram, Cerecellgram, Cartistem and Cupistem. The report also provides information on trends and pipelines. In addition to this, the report covers market drivers and challenges for stem cell research market.From:MarketResearchReportViews:0 1ratingsTime:01:21More inScience Technology
Go here to see the original:
Stem Cell Therapy Market in Asia-Pacific to 2018 Market Research Report - Video
Posted: December 22, 2012 at 12:49 pm
Hemp, Inc. is proud to announce the naming of BioSwan, Inc., a new spin-off of Hemp, Inc., dedicated to improving the quality of life via its proprietary all natural formulations and modalities designed to increase the bodys production of pluripotent adult stem cells, according to the Kimble Group.
Las Vegas, NV (PRWEB) December 21, 2012
Bruce Perlowin, CEO of Hemp, Inc., stated, "This could be an enormous benefit to Hemp, Inc. shareholders. While our research uncovered the valuable herbal blends that increase the specific stem cells, it is outside of Hemps core business and detracts from the management teams ability to focus. By spinning it off, the shareholders receive stock in BioSwan, Inc. This spinoff will have a dedicated and focused management team completely separate from Hemp, Inc. thereby allowing Hemp, Inc. improved focus. Everyone wins."
The National Institute of Health resource for stem cell research defines Pluripotent as, The state of a single cell that is capable of differentiating into all tissues of an organism. Pluripotent adult stem cells are rare and generally small in number but can be found in a number of tissues.
Current adult stem cell research targets the capacity of the cells to divide or self-renew indefinitely. Bone marrow stem cell, whose quantity declines with age, has been found to be one of the rich sources of adult stem cells, and has been used in treating Spinal cord injury, Liver Cirrhosis, Chronic Limb Ischemia, and Endstage heart failure. Adult stem cell treatments have been successfully used for many years to treat leukemia and related bone/blood cancers through bone marrow transplants. Adult stem cells are also used in veterinary medicine to treat tendon and ligament injuries in horses.
The National Institute of Health website states: Imagine if doctors were able to reverse age-related, chronic degeneration and bring the body back to its original health and vigor. The website continues, A study in mice found that function could be restored to injured muscle tissue by reactivating existing stem cells rather than transplanting new ones and that, The ability to reactivate dormant adult stem cells continues to be investigated.
Hemp, Inc. President David Tobias continued, "Aging is an issue that effects everyone, and it is gratifying to be able to participate and assist in a venture to improve health and the quality of life."
Lynita Kimble The Kimble Group, LLC (202) 695-2077 Email Information
More here:
Hemp, Inc. Announces BioSwan, Inc. -- An Update on One of its Spinoffs
Posted: December 22, 2012 at 12:49 pm
Queensland researchers have developed a way to identify breast cancer stem cells suspected of being the trigger for cancer growth.
Researchers from Griffith University and the Queensland Institute of Medical Research (QIMR) are working towards making breast cancer stem cells the target of specific cancer therapies, to improve treatment outcomes.
"We have described a method to identify specific proteins which are found in those stem cells, so it may be possible to identify their location and study them," Griffith University's Associate Professor Alejandro Lopez said on Friday.
"This will help us establish why breast cancer stem cells are different from other cells and potentially how to stop them from developing into cancer."
Professor Jeff Gorman from QIMR's Protein Discovery Centre said the research was an example of scientific collaboration at its best.
"It's the perfect marriage of biology and technology," he said.
QIMR's Protein Discovery Centre is one of the most advanced laboratories in Australia for the study of proteins and their effects on a range of infectious diseases and cancers.
Read more from the original source:
Breakthrough on breast cancer stem cells
Posted: December 22, 2012 at 12:49 pm
Mesenchymal (MSC) stem cells send out homing signals that recruit other stem cells and mobilize them to heal wounds, researchers at the Chicago Medical School at Rosalind Franklin University of Medicine and Science have discovered. MSC stem cells are better suited to initiating the healing process rather than repairing tissue damage themselves, the researchers explain in an article published today in Stem Cells Translational Medicine.
Durham, NC (PRWEB) December 21, 2012
Scientists Daniel Peterson and Laura Shin used MSC cells extracted from human bone marrow and grafted them into wounds of healthy mice and mice with diabetes. Mice in both groups each had two separate wounds to better allow the researchers to study the precise role the cells played in healing.
Some mice in each group received MSC cells in one wound while others did not receive the cells at all.
After studying the differences in healing, signaling and cell populations in the mice, Peterson and Shin learned that both normal and impaired mice given MSC cells healed more quickly, even in wounds that did not receive direct MSC cell grafts.
The mice that received MSC cells demonstrated a systemic response, Peterson said. This suggests that the key to repairing injured tissue does not hinge on where you place the MSC cells in the body, but on learning exactly how the MSC cells recruit their counterparts already in the body.
Researchers have investigated the behavior of MSC cells in a wide range of clinical trials including studies related to Crohns disease, Type 1 diabetes, bone defects and heart muscle disease. However, although MSC cells have come to be regarded as a magic bullet for tissue repair, no one until now has been able to explain how they do the job.
Discovering more about the signals MSC cells use to trigger the bodys own stem cells to heal could lead to new cell-free therapies, Peterson said. For example, scientists could develop treatments using small molecules or drugs as an alternative to costly cell-mediated therapies.
These findings broaden our view of therapeutic targets to include the host response, he said. The improvement in impaired and normal wound healing has significant clinical relevance for all wounds, chronic and acute.
This study indicates that signals within the wound bed may be activated after engraftment, suggesting that controlling mobilization is a key to success in future therapies, said Anthony Atala, MD, Editor of Stem Cells Translational Medicine and director of the Wake Forest Institute for Regenerative Medicine.
Posted: December 22, 2012 at 12:49 pm
REDWOOD CITY, Calif.--(BUSINESS WIRE)--
OncoMed Pharmaceuticals, Inc., a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, today announced that patient dosing has begun in a Phase 1 clinical trial of OMP-52M51 in patients with hematologic cancers. OMP-52M51 is OncoMeds fifth product candidate to enter clinical development. OMP-52M51 is a proprietary monoclonal antibody that targets the Notch1 receptor. Enrollment of the first patient in the Anti-Notch1 Phase 1 trial has triggered a $4 million milestone payment from the companys strategic collaborator GlaxoSmithKline (GSK).
The first Phase 1 clinical trial of OMP-52M51 is an open-label dose escalation and expansion study in patients with hematologic cancers. These patients are assessed for safety, pharmacokinetics, pharmacodynamics, and initial evidence of efficacy, and the clinical trial will also assess a predictive biomarker-based patient selection approach. OncoMed also has filed an additional IND application with the FDA to evaluate this monoclonal antibody in patients with solid tumors.
The trial is being conducted at several sites in the United States including Sarah Cannon Research Institute (SCRI) in Nashville, Tennessee. According to Dr. Ian Flinn of SCRI, who treated the first patient with OMP-52M51, It is exciting to bring a novel antibody such as OMP-52M51 that targets the Notch pathway, a key cancer stem cell pathway, into the clinic. There is significant scientific evidence to suggest that Notch1 could be an important therapeutic target in hematological malignancies, and we look forward to generating clinical data that might help patients with these cancers. The biomarker strategy employed in this study is also quite innovative.
We continue to execute on our core strategy of discovering and advancing novel product candidates that target cancer stem cells, said Paul Hastings, President and Chief Executive Officer of OncoMed Pharmaceuticals. OncoMeds clinical pipeline is broad, and with the addition of this novel Anti-Notch1 antibody, we now have 5 product candidates in the clinic, several which are advancing towards Phase 2 testing. We have made significant progress in building and developing our pipeline, and we look forward to generating important clinical data across each of our product candidates now being tested in humans.
About OMP-52M51
OMP-52M51 is a humanized monoclonal antibody targeted to the Notch1 receptor that has shown substantial anti-tumor and anti-CSC activity in Notch-dependent hematologic malignancies and solid tumors in preclinical studies. Certain hematologic malignancies have mutations that increase Notch1 signaling activity and may be a primary driver of tumor growth, as well as resistance to chemotherapy. Predictive biomarker tests have been identified that enable analyses of potential predictive biomarkers in clinical trials for OMP-52M51 to identify those subsets of patients with certain hematologic malignancies or certain solid tumors that may benefit most from the product candidate. OMP-52M51 is part of OncoMeds strategic collaboration with GSK. In December 2007, OncoMed and GSK entered into a broad strategic alliance to discover and develop novel product candidates targeting CSCs via Notch pathway signaling modulation. GSK retains an option through the end of certain Phase 1 or certain Phase 2 clinical trials to obtain an exclusive license to OMP-52M51.
About Cancer Stem Cells
Cancer stem cells, or CSCs, are the subpopulation of cells in a tumor responsible for driving growth and metastasis of the tumor. CSCs, also known as tumor-initiating cells, exhibit certain properties which include the capacity to divide and give rise to new CSCs via a process called self-renewal and the capacity to differentiate or change into the other cells that form the bulk of the tumor. Common cancer drugs target bulk tumor cells but have limited impact on CSCs, thereby providing a path for recurrence of the tumor. OncoMeds product candidates target CSCs by blocking self-renewal and driving differentiation of CSCs toward a non-tumorigenic state, and also impact bulk tumor cells. OncoMed believes its product candidates are distinct from the current generations of chemotherapies and targeted therapies, and have the potential to significantly impact cancer treatment and the clinical outcome of patients with cancer.
About OncoMed Pharmaceuticals
Posted: December 22, 2012 at 5:47 am
After the first description of a patient recognized as a MPS case was made in 1917, several similar cases were described and identified. Observations reported in the middle of the twentieth century concerning the presence of acid mucopolysaccharides (later called glycosaminoglycans, or GAGs) in tissues and especially in urine of patients were instrumental in providing an identity for these diseases, which became referred as "mucopolysaccharidoses" (MPS). In the late 1960's it was demonstrated that MPS were caused by defects in the breakdown of GAGs, and the specific enzyme deficiencies for the 11 types and subtypes of MPS were identified thereafter. Genes involved in the MPS were subsequently identified, and a large number of disease-causing mutations were identified in each one. Although ...
MedWorm Sponsor Message: Find the best Christmas presents and January Sales in the UK with this simple shopping directory.
Posted: December 21, 2012 at 10:39 pm
"Cell therapy products derived from adipose tissue have some unique processing issues with regard to obtaining accurate cell counts. This is because processing methods may not only show us the nucleated stromal vascular fraction (SVF) cells but also the micellular and microvesicle particles. This is true for both veterinary and human clinical products, and poses special concerns for in-clinic processing where the cell therapy dose is correlated with cell numbers and other QC data is not especially useful.
In this study, multiple cell counting methods were compared for SVF cell reparation that were derived from canine adipose tissue using commercially-available rocessing kits. The data clearly showed that many non-nucleated particles appear cell-like by size and shape, and can lead to counting errors with automated counters. In addition, certain reagents important to processing can have properties wherein the reagents alone (e.g., lecithin) may be counted as cells. The most accurate cell numbers were from hemocytometer-counting of cells stained with 4´,6-diamidino-2-phenylindole (DAPI) which shows the nuclei in concert with a viability stain such as trypan blue. The data clearly showed that care must be taken when counting cells used as a therapeutic dose."
This is an important issue particularly as it pertains to autologous cell-based treatments produced by point-of-care devices and/or kits. I encourage you to read the paper.
Morrison DG, Hunt DA, Garza I, Johnson RA, Moyer MP*. Counting and Processing Methods Impact Accuracy of Adipose Stem Cell Doses. BioProcess J, 2012; 11(4): 4-17.
* Dr. Moyer is CEO and Chief Science Officer for INCELL Corporation, 12734 Cimarron Path, San Antonio, Texas 78249 USA. http://www.incell.com
